FDA
-
-
-
-
-
-
-
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
-
-
-
-
-
-
-
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
-
-
-
-
-
-
-
Wuxi Biologics (2269:HK) (WXXWY) PT Lowered to HK$28 at JPMorgan
-
-
-
-
-
-
-
WuXi Biologics Reports Solid 2023 Interim Results
-
-
-
-
-
-
-
WuXi Biologics Achieved Record Growth and Profitability in 2021
-
-
-
-
-
-
-
WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services
-
-
-
-
-
-
-
WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa
-
328,099 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

